BRPI0504445A - composição de trombina e processo para a sua preparação - Google Patents

composição de trombina e processo para a sua preparação

Info

Publication number
BRPI0504445A
BRPI0504445A BRPI0504445-6A BRPI0504445A BRPI0504445A BR PI0504445 A BRPI0504445 A BR PI0504445A BR PI0504445 A BRPI0504445 A BR PI0504445A BR PI0504445 A BRPI0504445 A BR PI0504445A
Authority
BR
Brazil
Prior art keywords
preparation
thrombin
thrombin composition
stable
composition
Prior art date
Application number
BRPI0504445-6A
Other languages
English (en)
Inventor
Juan Ignacio Jorquera Nieto
Pere Ristol Debart
Jesus Fernandez Rodriguez
Isabel Bravo Camison
Rafael Lopez Gomez
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34384852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0504445(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of BRPI0504445A publication Critical patent/BRPI0504445A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

"COMPOSIçãO DE TROMBINA E PROCESSO PARA A SUA PREPARAçãO". Uma composição de trombina estável compreende trombina purificada, albumina humana e um sal neutro, sendo o produto resultante estável quando armazenado como um liofilizado ou congelado e é ajustado para uma intensidade nominal de 500 IU de trombina, ou mais, por ml de solução, estando a albumina humana em uma concentração de mais que 0,05% (p/v) e, preferentemente, entre 0,1% (p/v) e 1% (p/v).
BRPI0504445-6A 2004-10-22 2005-10-21 composição de trombina e processo para a sua preparação BRPI0504445A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200402523A ES2226587B1 (es) 2004-10-22 2004-10-22 Composicion de trombina estable.

Publications (1)

Publication Number Publication Date
BRPI0504445A true BRPI0504445A (pt) 2006-06-27

Family

ID=34384852

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0504445-6A BRPI0504445A (pt) 2004-10-22 2005-10-21 composição de trombina e processo para a sua preparação

Country Status (14)

Country Link
US (2) US20060088518A1 (pt)
EP (1) EP1649867B8 (pt)
JP (1) JP5105734B2 (pt)
AR (1) AR051396A1 (pt)
AU (1) AU2005225085B2 (pt)
BR (1) BRPI0504445A (pt)
CA (1) CA2523844C (pt)
ES (2) ES2226587B1 (pt)
HU (1) HUE052760T2 (pt)
MX (1) MXPA05011283A (pt)
NZ (1) NZ543084A (pt)
PL (1) PL1649867T3 (pt)
PT (1) PT1649867T (pt)
UY (1) UY29172A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2775974T3 (es) * 2006-06-26 2020-07-28 Omrix Biopharmaceuticals Inc Eliminación de virus por nanofiltración
CA2716872C (en) 2008-02-29 2015-02-10 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
JP5437236B2 (ja) 2008-04-16 2014-03-12 一般財団法人化学及血清療法研究所 トロンビン固定化生体吸収性シート製剤の製造方法
ES2682302T3 (es) 2010-06-01 2018-09-19 Baxter International Inc Proceso para la producción de composiciones hemostáticas secas y estables
JP5973997B2 (ja) 2010-06-01 2016-08-23 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 乾燥した安定な止血用組成物を作製するためのプロセス
AU2011260260B2 (en) 2010-06-01 2015-09-03 Baxter Healthcare S.A. Process for making dry and stable hemostatic compositions
CN104159527B (zh) 2012-03-06 2017-04-12 弗罗桑医疗设备公司 包含止血糊剂的压力容器
RU2636240C2 (ru) 2012-06-12 2017-11-21 Ферросан Медикал Дивайсиз А/С Сухая гемостатическая композиция
US9149529B2 (en) 2012-10-24 2015-10-06 Orthovita, Inc. Stable compositions containing thrombin and methods for preparation and use thereof
NZ708737A (en) * 2012-12-03 2019-06-28 Omrix Biopharmaceuticals Ltd Thrombin solution and methods of use thereof
US9212357B2 (en) 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof
JP6390873B2 (ja) 2013-06-21 2018-09-19 フェッローサン メディカル ディバイス エー／エス 減圧膨張させた乾燥組成物およびそれを保持するためのシリンジ
BR112016013322B1 (pt) 2013-12-11 2020-07-21 Ferrosan Medical Devices A/S métodos para preparação de uma composição seca e para reconstituir uma composição seca, composição seca, uso de uma composição seca, e, kit
BR112017007466B1 (pt) 2014-10-13 2021-03-02 Ferrosan Medical Devices A/S método para preparar uma composição seca, método para reconstituir a composição seca, pasta, composição seca, recipiente, kit homeostático, e, uso de uma composição seca
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
TW201702385A (zh) * 2015-03-13 2017-01-16 崇謹 孫 穩定凝血酶之方法及其組合物
CA2986981A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
EP4321182A3 (en) 2018-05-09 2024-05-29 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition
CN118785918A (zh) 2021-12-23 2024-10-15 广州倍绣生物技术有限公司 喷雾干燥的凝血酶
CN118401262A (zh) 2021-12-30 2024-07-26 巴克斯特国际公司 用于纤维蛋白密封剂的纤维蛋白原和凝血酶溶液以及纤维蛋白密封剂试剂盒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5639782A (en) * 1979-09-04 1981-04-15 Dai Ichi Pure Chem Co Ltd Stabilization of thrombin
US4696812A (en) * 1985-10-28 1987-09-29 Warner-Lambert Company Thrombin preparations
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
JPH0813750B2 (ja) 1990-03-01 1996-02-14 持田製薬株式会社 経口用トロンビン製剤
FR2679251B1 (fr) * 1991-07-18 1993-11-12 Nord Assoc Essor Transfusion San Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique.
AU683834B2 (en) * 1991-12-31 1997-11-27 Zymogenetics Inc. Methods for producing thrombin
US5506127A (en) * 1994-09-21 1996-04-09 Proba; Zbigniew Therapeutic grade thrombin produced by chromatography
GB9503750D0 (en) * 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
JPH10215875A (ja) * 1997-02-06 1998-08-18 Mitsubishi Chem Corp 蛋白質の精製方法
US5981254A (en) * 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
AU7320300A (en) * 1999-09-27 2001-04-30 International Reagents Corporation Means of stabilizing thrombin and compositions
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
EP1649867B8 (en) 2021-09-08
HUE052760T2 (hu) 2021-05-28
ES2845143T3 (es) 2021-07-26
EP1649867B1 (en) 2020-11-25
AU2005225085A1 (en) 2006-05-11
EP1649867A1 (en) 2006-04-26
PL1649867T3 (pl) 2021-06-14
CA2523844C (en) 2012-06-19
ES2226587A1 (es) 2005-03-16
AU2005225085B2 (en) 2007-05-31
ES2226587B1 (es) 2005-12-16
JP5105734B2 (ja) 2012-12-26
PT1649867T (pt) 2021-02-03
AR051396A1 (es) 2007-01-10
UY29172A1 (es) 2006-04-28
CA2523844A1 (en) 2006-04-22
US20140322791A1 (en) 2014-10-30
MXPA05011283A (es) 2006-05-25
NZ543084A (en) 2007-03-30
ES2845143T8 (es) 2021-11-17
US9376674B2 (en) 2016-06-28
JP2006117678A (ja) 2006-05-11
US20060088518A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
BRPI0504445A (pt) composição de trombina e processo para a sua preparação
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
CL2010000606A1 (es) Uso de derivados de eritropoyetina en la preparacion de un medicamento util para proteger, mantener, mejorar o recuperar la viabilidad de celulas que responden a eritropoyetina en condiciones anomalas que afectan las celulas, tejidos u organos asociados; derivados de eritropoyetinas y composicion que las comprende (divisional de la solicitud 3188-2001).
BR0307329A (pt) inibidores de cicloalquila da função do canal de potássio
BRPI0317696B8 (pt) composição para branqueamento
BR0014384A (pt) Compostos para o tratamento da isquémia
ES2570599T3 (es) Composición suave para desinfección cutánea
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
YU18899A (sh) L-nukleozidi purina, njihovi analogoni i primena
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
CY1109168T1 (el) Συνθεση νατριουχου φονταπαρινοξης υψηλης καθαροτητας
BR9810450A (pt) Derivados de ácido barbitúrico com atividade antimetastática e antitumor
EA200500804A1 (ru) Топические противоинфекционные композиции
DE69832710D1 (de) Nicht-irritierende zusammensetzung zur behandlung des aknes und andere hautzustände
BR9908301A (pt) Derivados de indol e composições farmacêuticas que compreendem os mesmos
YU19399A (sh) Lokalni anestetik za spoljnu upotrebu
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
ES2124983T3 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
BR0213878A (pt) Processo para a formação de sólidos de ibuprofeno
SI1755630T1 (sl) Farmacevtski sestavki iz lisaja bradovca (Usnea barbata) in sentjanzevke (Hypericum perforatum) kottudi njihova uporaba
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
CL2004000765A1 (es) Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: GRIFOLS, S.A. (ES)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B15W Others matters related to applications: legal action concerning application

Free format text: INPI NO 52402.009734/2020-87 ORIGEM: JUIZO FEDERAL DA 9A VF DO RIO DE JANEIRO (TRF2) PROCESSO NO: 00408.055151/2020-74 (REF. 5046129-08.2020.4.02.5101) NULIDADE DO ATO ADMINISTRATIVO QUE MANTEVE O INDEFERIMENTO DO PEDIDO DE PATENTE AUTOR: GRIFOLS S.A. REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI